#China #Shanghai #Kelun-Biotech #Harbour BioMed #HBM7575

Introduction

Harbour BioMed and Kelun-Biotech have announced a significant milestone in asthma treatment with the approval from China's National Medical Products Administration (NMPA) for their Investigational New Drug (IND) application regarding the novel antibody HBM7575/SKB575. This new compound is a long-acting bispecific antibody designed specifically to target thymic stromal lymphopoietin (TSLP) alongside another undisclosed target. This partnership is pivotal as it marks a forward leap in addressing the growing prevalence of asthma, which currently affects approximately 300 million individuals globally.

Background

Asthma is a common, chronic respiratory condition characterized by difficulty in breathing, wheezing, and coughing, often leading to diminished quality of life. Established treatments primarily include inhaled corticosteroids (ICS) and bronchodilators. Although helpful, these current therapies are often insufficient for a substantial number of patients, leaving a clear demand for newer, more effective interventions that function optimally at the root of the disease processes.

Innovative Mechanism of HBM7575/SKB575

The HBM7575/SKB575 antibody is designed to exhibit a dual mechanism of action. It works by obstructing the interaction between TSLP and its receptor, ultimately disrupting TSLP-mediated signaling pathways that contribute to asthma. Additionally, it also binds and inhibits an undisclosed target, which is expected to produce a synergistic effect that enhances control over inflammation compared to therapies targeting a single pathway. Such a dual approach signifies a potential advancement in drug efficacy and patient outcomes.

Development Progress

Following the initiation of a Phase 1 clinical study, the first participant has already been administered HBM7575/SKB575 for atopic dermatitis, showcasing the antibody's potential versatility across different inflammatory conditions beyond asthma alone. With the NMPA's recent approval for asthma treatment, Harbour BioMed's CEO, Dr. Jingsong Wang, expressed enthusiasm about the swift progression of this molecule into further clinical applications, highlighting the urgency to redefine treatment paradigms for chronic immune-mediated diseases. The overall clinical plan indicates a robust commitment towards unlocking the full potential of this therapeutic.

Future Prospects

As the compound is being propelled towards human trials, its promising pharmacokinetic properties suggest prolonged dosing intervals potentially exceeding three months, a factor that could significantly enhance patient compliance and overall treatment efficacy. The strategic partnership between Harbour BioMed and Kelun-Biotech, wherein Kelun-Biotech spearheads the design and commercialization while Harbour BioMed provides developmental support, strengthens the likelihood of driving this innovative treatment through clinical stages effectively.

About Harbour BioMed and Kelun-Biotech

Harbour BioMed is recognized internationally for its dedication to discovering and developing breakthrough antibody therapeutics used in various therapeutic areas including oncology and immunology. Its unique antibody technology, notably the Harbour Mice® platform, aids in creating fully human monoclonal antibodies that can achieve effects beyond traditional therapies. Meanwhile, Kelun-Biotech is focused on developing innovative biological and small molecule drugs to meet unmet medical needs across solid tumors and autoimmune diseases, among other critical areas. Their combined efforts present a powerful front in the global pursuit of next-generation therapeutic solutions.

Conclusion

The NMPA approval of HBM7575/SKB575 signifies a beacon of hope for asthma patients, opening doors to more effective treatment strategies. As clinical trials progress, the biopharmaceutical community will keenly watch how this collaboration unfolds, potentially transforming asthma management paradigms, particularly for those inadequately served by current therapies.